Comparative Pharmacology
Head-to-head clinical analysis: INDOMETHACIN SODIUM versus NAPROSYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDOMETHACIN SODIUM versus NAPROSYN.
INDOMETHACIN SODIUM vs NAPROSYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, leading to anti-inflammatory, antipyretic, and analgesic effects.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This results in decreased inflammation, pain, and fever.
Intravenous: 0.5 mg/kg every 12 hours or 0.25 mg/kg every 6 hours for patent ductus arteriosus closure in neonates. Oral/immediate-release: 25-50 mg two to three times daily. Extended-release: 75 mg once daily or 75 mg twice daily. Maximum daily dose: 200 mg.
250-500 mg orally twice daily; maximum 1500 mg/day. For extended-release: 750-1000 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life: 4.5 hours (range 2.6–11.2 hours); half-life may be prolonged in neonates, elderly, and renal impairment
Terminal elimination half-life is 12-17 hours. This long half-life allows twice-daily dosing, but may lead to drug accumulation in elderly or renally impaired patients.
Renal (60% as unchanged drug and metabolites, predominantly glucuronide conjugate); fecal (33%, primarily via biliary secretion); <5% unchanged in urine
Renal excretion of conjugated metabolites accounts for approximately 95% of a dose, with 1-2% as unchanged naproxen. Fecal excretion is minimal (<5%).
Category D/X
Category C
NSAID
NSAID